Apatinib Plus Temozolomide for Recurrent Glioblastoma: An Uncontrolled, Open-Label Study

OBJECTIVE: This study aimed to determine the efficacy and tolerability of apatinib plus dose-dense temozolomide (TMZ) as first-line treatment for recurrent glioblastoma (rGBM). METHODS: Patients with rGBM were enrolled in this study. Patients were subjected to concurrent treatment of apatinib (500 m...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yong, Meng, Xiangji, Zhou, Shizhen, Zhu, Yufang, Xu, Jun, Tao, Rongjie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6899067/
https://www.ncbi.nlm.nih.gov/pubmed/31819537
http://dx.doi.org/10.2147/OTT.S226804

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6899067/
https://www.ncbi.nlm.nih.gov/pubmed/31819537
http://dx.doi.org/10.2147/OTT.S226804

Ejemplares similares